Should I Buy ZVRA? ZVRA 2026 Analysis

Should You Buy Zevra Therapeutics Inc (ZVRA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

8.860

1 Day change

2.67%

52 Week Range

13.160

Analysis Updated At

2026/01/26

Zevra Therapeutics Inc (ZVRA) is not a strong buy at the moment for a beginner investor with a long-term horizon. While the stock has potential upside based on analyst ratings and the recent distribution agreement, the lack of strong trading signals, weak financial performance, and neutral sentiment from hedge funds and insiders make it prudent to hold off on immediate investment.

Technical Analysis

The MACD is positive but contracting, indicating a weakening bullish momentum. RSI is neutral at 55.89, and moving averages are converging, signaling indecision. The stock is trading close to its pivot level of 8.86, with resistance at 9.441 and support at 8.28. These indicators suggest no strong trend currently.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Options data shows a bullish sentiment with a low put-call ratio, but the overall trading volume is not significant enough to confirm strong market interest.

Technical Summary

Sell

Buy

Positive Catalysts

H.C. Wainwright reiterated a Buy rating with a $26 price target, citing the expanded access distribution agreement with Uniphar for Miplyffa. This deal could unlock new revenue streams, which are not yet priced into the stock.

Neutral/Negative Catalysts

Financial performance in Q3 2025 shows a significant drop in net income (-98.36% YoY) and EPS (-98.55% YoY), despite a revenue increase. Gross margin also dropped significantly, raising concerns about profitability. Analyst price targets have been lowered recently by Canaccord and Cantor Fitzgerald, reflecting cautious sentiment.

Financial Performance

In Q3 2025, revenue increased by 605.36% YoY to $26.06M, but net income dropped to -$544K (-98.36% YoY), and EPS fell to -0.01 (-98.55% YoY). Gross margin also declined significantly to 94.04%, highlighting profitability challenges.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts maintain a Buy or Overweight rating, with price targets ranging from $24 to $26. However, recent target reductions from Canaccord and Cantor Fitzgerald indicate tempered expectations due to challenges in the European market for Miplyffa.

6 Analyst Rating

Wall Street analysts forecast ZVRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZVRA is 24 USD with a low forecast of 21 USD and a high forecast of 26 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

Current: 8.630

Low

Averages

High

Current: 8.630

Low

Averages

High

H.C. Wainwright

Buy

maintain

$26

AI Analysis

2025-12-30

Reason

H.C. Wainwright

Price Target

$26

AI Analysis

2025-12-30

maintain

Buy

Reason

H.C. Wainwright reiterates a Buy rating on Zevra Therapeutics (ZVRA) with a $26 price target after the company signed an exclusive expanded access distribution agreement with Uniphar (UPR). The deal adds new territories to Zevra's current expanded access program for Miplyffa for Niemann-Pick disease type C patients, the analyst tells investors in a research note. H.C. Wainwright believes the expanded opportunity for Miplyffa is currently not priced into the stock or reflected in consensus expectations.

Canaccord

Buy

downgrade

$25 -> $24

2025-11-06

Reason

Canaccord

Price Target

$25 -> $24

2025-11-06

downgrade

Buy

Reason

Canaccord lowered the firm's price target on Zevra Therapeutics to $24 from $25 and keeps a Buy rating on the shares. The firm lowered its target on a softening Europe Miplyffa ramp.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ZVRA

Unlock Now

ZVRA Should I Buy

ZVRA Should I Buy

Should You Buy Zevra Therapeutics Inc (ZVRA) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch